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studied, the mechanisms of its initiation and chronic extension still 
remain to be resolved. Yet, it is clear that development of fibrosis 
after radiation cannot simply be explained by the function of one 
molecule, but requires the interplay of several cytokines and growth 
factors and multiple cell types.  
Our studies have identified the TGF-β co-receptor endoglin as new 
player in radiation-induced fibrosis development in the kidney. Mice 
expressing halved levels of endoglin (Eng+/-mice) displayed reduced 
fibrosis, but also less vascular damage after a single dose of kidney 
irradiation compared to irradiated Eng+/+ mice. This was accompanied 
by decreased mRNA expression of Tgfb1 and pro-fibrotic downstream 
targets such as Pai-1, Ctgf or Col3A1. We also noticed that 
development of fibrosis in the kidney was accompanied by infiltration 
of inflammatory cells, mainly macrophages. Macrophages are crucial 
for tissue repair, but may also promote kidney fibrosis by secreting 
pro-fibrotic growth factors and cytokines as shown in several models 
of kidney disease. Macrophage numbers were significantly upregulated 
in both irradiated Eng+/+ and Eng+/- kidneys; however, the upregulation 
was less pronounced in Eng+/- mice. In addition, expression of 
macrophage-expressed pro-inflammatory, pro-fibrotic and anti-
angiogenic cytokines interleukin 1-beta (Il1b) and interleukin 6 (Il6) 
was strongly reduced in the irradiated kidneys of Eng+/- compared to 
Eng+/+ mice.  
As endoglin is not only expressed on endothelial cells, but also on 
monocytes/macrophages, we are currently investigating whether 
changed endothelial cell function or an altered macrophage 
phenotype contributes to differential fibrosis formation in Eng+/+ and 
Eng+/-mice. We are also analysing whether macrophage depletion 
prevents fibrosis formation after kidney irradiation. Furthermore, we 
are testing whether the anti-inflammatory, immunomodulatory and 
anti-fibrotic drug Thalidomide impedes the development of radiation-
induced kidney fibrosis. 
In summary, we suggest that endoglin mediates the inflammatory 
response in irradiated tissues by regulating macrophage infiltration 
and cytokine production thereby contributing to the development of 
irradiation-induced kidney fibrosis.  
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Brachytherapy has benefited considerably from advances in imaging 
techniques in recent times. Tumour volumetric-based radiation 
planning based on excellent delineation of tumour anatomy has much 
improved our ability to target malignant tissue whilst sparing non-
malignant tissues. The highly conformal nature of Brachytherapy has 
further benefited from newer functional imaging techniques based on 
recognition of the altered biological and molecular processes 
occurring within tumour tissue. New paradigms for treatment planning 
and radiation delivery are now becoming possible based on the 
potential to define areas of varying functional activity within the 
anatomical tumour mass. Established 3D tumour volumes generated by 
morphological imaging techniques can now be modified by new 
information provided by functional imaging such as PET and MRI. 
Brachytherapy for prostate and Head & Neck cancers can benefit from 
data that quantifies areas of cellular and molecular disruptions within 
the tumour mass and thus offers the potential to individualise the 
Brachytherapy radiotherapy plan for each patient. 
Prostate Brachytherapy includes both High Dose Rate and Low Dose 
Rate techniques and has become widely adopted as a valid treatment 
for prostate tumours. Historically, imaging has played a relatively 
small role in the management of clinically localized prostate cancer 
but in more recent years, medical imaging techniques, such as TRUS, 
CT and MRI have improved the clinical management of patients with 
prostate cancer. Brachytherapy offers the possibility of better local 
treatment with less morbidity and improved outcomes; more accurate 
imaging has contributed to better staging and patient selection as well 
as more accurately image-guided treatment delivery.  
In the non-surgical treatment of head and neck tumours, 
Brachytherapy offers an excellent treatment for organ-preservation 
with local tumour control. Image guidance is central to the 
optimization of this treatment with careful dose escalation facilitated 
by accurate delineation of tumour and structures at risk. Adaptive 
image-guided Head & Neck Brachytherapy can complement newer 
surgical techniques and better understanding of tumour biology in this 
area will incorporate newer boost techniques also. 
The inherent goal of Brachytherapy is to safely deliver adequate 
radiation to those  areas of tumour tissue that are considered 
necessary based on our current understanding of tumour biology and 
radiation response. Imaging is central to the success of this 
treatment. 
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Before the era of breast conservation therapy using external beam 
radiotherapy (EBRT) and before the invention of linear accelerators 
and its widespread use in breast cancer treatment, brachytherapy 
using radium needles was the first method of breast irradiation. 
Interstitial breast implants started at the beginning of the XXth 
century either as mono-therapy or associated to surgery.  
Over the years, breast brachytherapy was less and less used but  it 
remained an option as a boost toEBRT. Nowadays with the increase 
use of partial breast irradiation, breast brachytherapy is gaining more 
importance.  Unlike prostate, breast brachytherapy is not widely 
practiced because it was always considered by many to be too 
operator and skill- dependent, partly because of the lack of easy and 
precise imaging.  It is evident that for more accuracy, imaging is 
necessary in breast brachytherapy as it is in EBRT, to plan and 
optimize the treatment. The need of accuracy is even more important 
in brachytherapy because it provides the most conformal coverage of 
tumor and normal tissue sparing radiotherapy technique.  
So in this era of highly targeted radiotherapy, breast brachytherapy 
faces the same challenges of volume delineation at each step of the 
process: in pre-planning, during implant and at dosimetry. The first 
step is the identification of the surgical bed to be implanted. This is 
not an easy task as reflected by the numerous papers in the 
literature. At the time of brachytherapy the cavity is often collapsed 
and difficult to find. We conducted a phase II study Using MRI imaging 
to help in the delineation of the surgical bed and therefore help to 
plan precisely where to place the implant. The second step is the 
precise placement of the interstitial needles into the breast around 
the target. This is of great importance since it will, in a way, 
determined the dosimetry. Ultrasound can be used as a step-by-step 
procedure. As in prostate brachytherapy a real-time imaging during 
the procedure would be ideal. The ultimate step, the dosimetry, is to 
maximize the dose to the target volumes and to minimize the dose to 
the adjacent organs at risk. At this step the quality of imaging is 
important for the delineation of the volumes and for reconstruction of 
the material implanted. CT scan allows implant reconstruction very 
easily but MRI allows accurate surgical bed delineation. Therefore a 
robust image fusion capacity has to be available.  Ultimately, the goal 
would be to find a 3D imaging modality that could serve both purposes 
and couldbe integrated in the treatment planning system. 
This presentation is aimed to determine the role of modern imaging 
modalities in all the steps of interstitial breast brachytherapy. It is our 
opinion that more accurate imaging will help the wide application of 
interstitial brachytherapy for breast cavity boost, partial breast 
irradiation and second conservative treatment for in-breast 
recurrences.  
 
SP-0221   
Gynaecology 
J. Dimopoulos 
Metropolitan Hospital, Athens, Greece 
 
Abstract not received 
 
 SYMPOSIUM: EU PROJECTS 2  
  
SP-0222   
First clinical experience with head and neck and lung cancer 
patients within the ARTFORCE project 
H. Bartelink1, J.J. Sonke1 
1The Netherlands Cancer Institute - Antoni van Leeuwenhoek 
Hospital, Department of Radiation Oncology, Amsterdam, The 
Netherlands  
  
The ARTFORCE project (Adaptive and innovative Radiation Treatment 
FOR improving Cancer patients treatment outcomE) that now runs for 
more than a year, consists of two clinical trials, combined with 
fundamental research in molecular biology, i.e. predicting tumour 
response and physics: image guidance and dosimetry performed in a 
multi-institutional environment.   
The non-small cell lung cancer study aims to improve local control and 
test the hypothesis of iso-toxic dose redistribution. Patients are 
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randomized between dose-escalation of the entire primary tumour or 
to the high FDG uptake region inside the primary tumour. Plans are 
normalized to the same mean lung dose, while giving 66 Gy in 24 
fractions to involved lymph nodes. The trial has already accrued 66 
patients and will soon be extended to five participating centres. The 
head and neck trial investigates the impact of delivering a high 
radiation dose to the most active part of the tumour, as seen on the 
PET-CT scan by adaptive radiotherapy. Patients are randomized 
between a conventional IMRT and adaptive IMRT by redistribution of 
the radiation dose: with higher doses given to the most active part of 
the tumour and low doses at the border of the CTV. In the adaptive 
arm, the treatment plan is modified to account for anatomical 
changes occurring over the course of therapy. In a factorial design, 
patients are randomized between 1) conventional and adaptive 
radiotherapy and 2) radiotherapy plus cisplatin or cetuximab. The 
sensitivity for cisplatin and cetuximab is estimated by both molecular 
profiling research and the 3D measurement of 89- Zirconium uptake in 
the tumour. The first patient just completed the treatment with the 
combination of radiotherapy and cetuximab in the head and neck 
cancer study. Although this is a very sophisticated and intensive 
approach, the treatment has proceeded without problems. 
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There is growing concern about the possible long-term risks to 
radiotherapy patients from neutrons, which are generated as a by-
product either in high-energy photon beams, or proton beams.  The 
usual approach to estimating the risk from neutrons is to use ICRP risk 
factors and radiation weighting factors for neutrons.  There are a 
number of problems with this, and indeed the ICRP state clearly that 
their numbers are approximations, which should only be used for 
radiation protection guidelines, and not for individuals.  According to 
the ICRP scheme, the risk from neutrons is determined by means of 
the relative biological effectiveness (RBE) of neutrons compared to 
photons for which the risks are better known.  However there is 
considerable uncertainty about how RBE for neutrons varies with dose 
and neutron energy, or whether the RBE model is even appropriate.  
Two major reasons for this are that it is very difficult to obtain risk 
data in exposure situations where the neutron energy is confined to a 
narrow spectrum (or even well known), and the occurrence of risk 
events at the low doses of interest is very low giving poor statistics.  
Previous research on risks from neutron risk has mainly been single-
discipline.  That is, the results have been dependent on a single 
experimental or epidemiological approach.  By contrast, the ANDANTE 
project uses three different disciplines in parallel.  This is analogous 
to taking images of an object using three different imaging modalities 
and combining them to produce an image much sharper than any of 
the individual images.  The three parallel approaches are: 
Physics: a track structure model is used to contrast the patterns of 
damage to cellular macro-molecules from neutrons compared to 
photons.  The simulations reproduce the same energy spectra as are 
used in the other two approaches. 
Stem cell radiobiology: stem cells from thyroid, salivary gland, and 
breast tissue are given well characterised exposures to neutrons and 
photons.  A number of endpoints are used to estimate the relative risk 
of damage from neutrons compared to photons.  As well, irradiated 
cells will be transplanted into mice to investigate the incidence of 
progression into tumours.   
Epidemiology: the relative incidence rates of second cancers of the 
thyroid, salivary gland, and breast following paediatric radiotherapy 
(conventional radiotherapy for photons and proton therapy for 
neutrons) are investigated in a pilot single-institution study, leading to 
a multi-institution prospective study. 
The project has completed the first of its four years.  Progress on 
characterising the exposure beams, isolation and initial exposures of 
stem cells, and data collection for the epidemiological studies will be 
presented.  
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Out-of field neutron exposure of proton therapy might lead to 
enhanced formation of second cancer. The goal of the Andante 
project is to estimate the risk of second cancer from out-of field 
neutron exposure and compare this with other treatment modalities. 
This study focuses on two specific cancers that may be detected as 
second malignant neoplasms following pediatric radiotherapy:salivary 
gland and thyroid gland cancer. It has been suggested that adult stem 
cells are a critical target for radiation carcinogenesis. Therefore, in 
this study adult stem cells from murine salivary and thyroid glands 
were isolated and expanded in culture. Stem cell containing spheroids 
(multicellular 3D structures) could be obtained from both murine 
salivary and thyroid glands in non-adherent cultivation of cell 
suspensions of salivary and thyroid gland tissue in serum-free 
conditions. After digestion of spheroids into single cells, cells were 
exposed to different doses (0.1, 0.5, 1, 2, 5 Gy) of ϒ-irradiation. To 
determine transformation, in vitro self-renewal and differentiation 
capacity were investigated of irradiated cells and were compared to 
unirradiated cells. In addition, salivary and thyroid cells were isolated 
from inducible p53 knockout mice to test the carcinogenesis potential 
of the model. Transplantation of irradiated stem cells in photon-
irradiated salivary glands will be performed to get information on 
carcinogenic transformation in vivo. In the future, stem cells will be 
exposed to neutrons and will be compared to the exposure of photons.  
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Purpose/Objective: Intensity-modulated radiotherapy (IMRT) 
credentialing for the 22074-24071 Head and Neck (H&N) EORTC study 
was performed using the anthropomorphic head phantom from the 
Radiological Physics Center (RPC; RPCph). Institutions were also 
retrospectively requested to irradiate their own in-house phantom 
(Instph) using the same treatment plan in the framework of a Virtual 
Phantom Project (VPP) for IMRT credentialing. Both measurement and 
calculations for the RPCph and Instph were sent to the EORTC for 
central analysis using the digital quality assurance (QA) platform. 
Materials and Methods: Calculated and measured 2D dose matrices on 
the Instph were requested from centers and send to a dedicated 
secured EORTC uploader. RPC analyzed the credentialing 
measurements performed in the RPCph using the VPP metrics. Data 
from the RPCph and INSTph were thereafter centrally analyzed and 
inter-compared by the QA team using commercially available 
software. 
Results: Eighteen institutions participated to the VPP. The 
measurements of 6 (33%) institutions could not be analyzed centrally, 
as a result of incomplete datasets (n=4) or dose-matrix format issues 
(n=2). All other centers (n=12; 66%) could be credentialed successfully 
using the VPP protocol and the dose-gradient produced by the IMRT 
plans were acceptable in all cases using the RPC criteria. The same 
number of institutions (n=12) was successfully credentialed using the 
more stringent 5%/5 mm pass at the 90% pixel cutoff-level gamma 
analysis criteria. A passing rate of 84.8±13.1%, 97.8±3.2% and 
99.3±1.2% for the 3%/3 mm,5%/5 mm and 7%/4mm QA criteria, 
respectively, was observed with RPCph. A corresponding passing rate of 
93.5±5.4%, 98.9±1.5% and 99.4±1.2% for 3%/3 mm, 5%/5 mm and 
7%/4mm QA criteria , respectively, was observed with the VPP using 
Instph data. 
Conclusions: IMRT credentialing for H&N prospective trials using 
institutional phantom measurements is possible and was successful in 
all cases using the RPC passing criteria.  
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